Tempus AI, Inc. Class A (TEM)
NASDAQ:TEM
Want to see TEM full AI Analyst Report?
TEM Stock Chart & Stats
$55.87
-$0.17(-0.45%)
At close: 4:00 PM EST
$55.87
-$0.17(-0.45%)
Day’s Range― - ―
52-Week Range$41.73 - $104.32
Previous CloseN/A
Volume1.41M
Average Volume (3M)4.99M
Market Cap
$10.01B
Enterprise Value$9.94B
Total Cash (Recent Filing)$755.00M
Total Debt (Recent Filing)$815.71M
Price to Earnings (P/E)―
Beta3.11
Next Earnings
May 12, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.41
Shares Outstanding174,360,820
10 Day Avg. Volume6,292,065
30 Day Avg. Volume4,991,501
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)20.94
Price to Sales (P/S)8.09
P/FCF Ratio-43.03
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue7.82
Enterprise Value/Gross Profit11.23
Enterprise Value/Ebitda-44.71
Forecast
1Y Price Target
$72.71Price Target Upside30.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)-0.43
Revenue Forecast (FY)$1.59B
Bulls Say, Bears Say
Bulls Say
AI Product AdoptionCommercial deployment of AI-based imaging and algorithm tools that integrate into clinician workflows could increase product uptake and open new revenue streams as clinical adoption progresses.
Genomics And Diagnostic GrowthMigration to newer diagnostic platforms and expansion of minimal residual disease testing support higher testing volumes and improved per-test pricing, strengthening core diagnostics revenue.
Strategic PartnershipsExpanded collaborations with major pharmaceutical companies and academic centers could accelerate biomarker discovery and drive recurring revenue from de-identified clinical datasets and platform services.
Bears Say
Profitability PressureHigher planned operating expenses combined with ongoing net losses could continue to pressure margins and postpone the shift to sustained adjusted profitability.
Reimbursement UncertaintyEarly-stage reimbursement for certain genomic tests creates uncertainty around revenue realization and could delay the expected pricing benefits from new assays.
Valuation And Investor SentimentAnalyst price target reductions and a rise in measured stock risk may weaken investor confidence and exert downward pressure on the company’s market valuation.
Tempus AI, Inc. Class A News
TEM FAQ
What was Tempus AI, Inc. Class A’s price range in the past 12 months?
Tempus AI, Inc. Class A lowest stock price was $41.73 and its highest was $104.32 in the past 12 months.
What is Tempus AI, Inc. Class A’s market cap?
Tempus AI, Inc. Class A’s market cap is $10.01B.
When is Tempus AI, Inc. Class A’s upcoming earnings report date?
Tempus AI, Inc. Class A’s upcoming earnings report date is May 12, 2026 which is in 7 days.
How were Tempus AI, Inc. Class A’s earnings last quarter?
Tempus AI, Inc. Class A released its earnings results on Feb 24, 2026. The company reported -$0.04 earnings per share for the quarter, missing the consensus estimate of -$0.033 by -$0.007.
Is Tempus AI, Inc. Class A overvalued?
According to Wall Street analysts Tempus AI, Inc. Class A’s price is currently Undervalued.
Does Tempus AI, Inc. Class A pay dividends?
Tempus AI, Inc. Class A does not currently pay dividends.
What is Tempus AI, Inc. Class A’s EPS estimate?
Tempus AI, Inc. Class A’s EPS estimate is -0.2.
How many shares outstanding does Tempus AI, Inc. Class A have?
Tempus AI, Inc. Class A has 174,360,820 shares outstanding.
What happened to Tempus AI, Inc. Class A’s price movement after its last earnings report?
Tempus AI, Inc. Class A reported an EPS of -$0.04 in its last earnings report, missing expectations of -$0.033. Following the earnings report the stock price went down -7.317%.
Which hedge fund is a major shareholder of Tempus AI, Inc. Class A?
Currently, no hedge funds are holding shares in TEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tempus AI, Inc. Class A Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$72.71 (30.15% Upside)
$72.71 (30.15% Upside)
Blogger Sentiment
Bullish
TEM Sentiment 80%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 233.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
38.12%
12-Months-Change
Fundamentals
Return on Equity
-59.95%
Trailing 12-Months
Asset Growth
145.63%
Trailing 12-Months
Company Description
Tempus AI, Inc. Class A
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a strategic collaborations agreement with AstraZeneca and Pathos AI, Inc. to develop therapeutic programs in oncology. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
TEM Company Deck
TEM Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized robust multi-year growth drivers: strong diagnostic unit growth (Oncology +29%, MRD +56% Q/Q), accelerating data business with >$1.1B in TCV and 126% net revenue retention, positive 2026 guidance ($1.59B) and a path to higher ASPs and adjusted EBITDA. Key near-term constraints are reimbursement gating for MRD, moderation and lumpiness in Hereditary growth, and one-time impacts to some reported data growth figures. Overall, the positive revenue, contract backlog, AI/foundation-model progress, and strong customer retention materially outweigh the execution and reimbursement risks highlighted.View all TEM earnings summariesTEM Stock 12 Month Forecast
Average Price Target
$72.71
▲(30.15% Upside)
Technical Analysis
Ownership Overview
22.66% Insiders
8.95% Mutual Funds
3.09% Other Institutional Investors
49.77% Public Companies and Individual Investors